STUDY NUMBER: 2600080

Dear pioneer,

A study to **treat multiple sclerosis** will soon start at our research centre in Edegem.
Are you interested in participating and giving science a boost?
Hereby we would like to give you an overview of the study: duration of **± 9 weeks**.

In this group, the study medication will be administered **orally**.

During the study, a Holter monitor (a portable device that records heart activity) will be connected at certain time points.

Please note: this cohort may be cancelled at short notice.

INCLUSION CRITERIA

- **Last participation in other clinical study (last study medication*):**
  - **Group C:** not later than **27JUN2026** (90 days before first dosing date)

  **Be careful: Final study visit of the previous study needs to be performed to be able to participate at screening.*

- Healthy men and women **between: 18 and 55 years (inclusive)**
- BMI: between 18.5 – 32.0 kg/m² (inclusive)
  - Weight at least 50.0 kg
- Non-smoker or stopped smoking minimum 12 months before screening (including e-cigarettes and nicotine replacement products)
- Not using any medication, vitamins, or homeopathic substances
- Contraception:
  - **Fertile women:** from screening up to and including 38 days after the last administration of the study medication:
    - no egg donation
    - use of an effective method of contraception (e.g. oral contraceptive pill, intrauterine device, vaginal ring, etc.)
    - OR bilateral tubal ligation
    - OR a sterilized partner
    - OR abstinence from heterosexual intercourse
  - **Infertile women:**
    - postmenopausal (= no menstruation for at least 12 months)
    - OR removal of uterus
    - OR removal of both ovaries
    - OR removal of both fallopian tubes
  - **Men:** from screening up to and including 98 days after the last administration of the study medication:
    - no sperm donation
    - abstinence from sexual intercourse
    - **OR** use of a condom:
      - for any type of sexual intercourse
      - if you have undergone a vasectomy (sterilization)
      - AND if the female partner is of childbearing potential, she must use an effective method of contraception (e.g. oral contraceptive pill, intrauterine device, vaginal ring, etc.)
      - if the female partner has had both fallopian tubes ligated
      - if the female partner is not of childbearing potential
  - Men with a partner who is pregnant or breastfeeding are not allowed to participate in the study.

- You are not eligible to participate if you:
  - have a history of Hepatitis C, Gilbert's syndrome or HIV, or have an active Hepatitis B infection
  - have donated blood or plasma within the past 3 months, or have lost more than 400 mL of blood
  - have an allergy that requires treatment (hay fever is allowed provided that no medication is being taken). In case of uncertainty, this may be discussed with the physician during the screening visit.

- You will be asked to follow the restriction regarding physical activity, consumption of caffeine and alcoholic products.
- No participation in any of the previous groups of this study
- You are not *(family of)* an employee of the sponsor Immunic OR not *(family of)* an employee of SGS, who is directly involved in the study.

INTEREST IN PARTICIPATING

Registration for this study only indicates your interest and does not obligate you to participate, nor us to include you as a participant.

Thank you in advance for your interest and we hope to welcome you soon for study 2600080.

SGS CPU